Discontinuation of antidepressants in people with dementia and neuropsychiatric symptoms (DESEP study): Double blind, randomised, parallel group, placebo controlled trial

BMJ (Online)

Volumn 344, Issue 7851, 2012, Pages

  Bergh, Sverre ^a   Selbæk, Geir ^a,b   Engedal, Knut ^a,b,c  

^a INNLANDET HOSPITAL TRUST   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF OSLO   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; ESCITALOPRAM; PAROXETINE; PLACEBO; SERTRALINE; ANTIDEPRESSANT AGENT;

ALZHEIMER DISEASE; ARTICLE; CONTROLLED STUDY; DEMENTIA; DEPRESSION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MOOD; MULTICENTER STUDY; MULTIINFARCT DEMENTIA; NORWAY; NURSING HOME; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SYMPTOMATOLOGY; TREATMENT WITHDRAWAL; AGED; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE COURSE; GERIATRIC ASSESSMENT; METHODOLOGY; NEUROPSYCHIATRY; NEUROPSYCHOLOGICAL TEST; PSYCHOLOGICAL ASPECT;

AGED; AGED, 80 AND OVER; ANTIDEPRESSIVE AGENTS; DEMENTIA; DEPRESSION; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; FEMALE; GERIATRIC ASSESSMENT; HUMANS; MALE; NEUROPSYCHIATRY; NEUROPSYCHOLOGICAL TESTS; OUTCOME ASSESSMENT (HEALTH CARE); WITHHOLDING TREATMENT;

EID: 84859540254     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.e1566     Document Type: Article

References (33)

1. Selbaek G, Kirkevold O, Engedal K. The prevalence of psychiatric symptoms and behavioural disturbances and the use of psychotropic drugs in Norwegian nursing homes. Int J Geriatr Psychiatry 2007;222:843-9. (Pubitemid 47455265)
2. Wetzels R, Zuidema S, Jansen I, Verhey F, Koopmans R. Course of neuropsychiatric symptoms in residents with dementia in long-term care institutions: a systematic review. Int Psychogeriatr 2010;22:1040-53.
3. Selbaek G, Kirkevold O, Engedal K. The course of psychiatric and behavioral symptoms and the use of psychotropic medication in patients with dementia in Norwegian nursing homes-a 12-month follow-up study. Am J Geriatr Psychiatry 2008;16:528-36.
4. Ballard C, Corbett A. Management of neuropsychiatric symptoms in people with dementia. CNS Drugs 2010;24:729-39.
5. Sink KM, Holden KF, Yaffe K. Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence. JAMA 2005;293:596-608. (Pubitemid 40171242)
6. Pollock BG, Mulsant BH, Rosen J, Sweet RA, Mazumdar S, Bharucha A, et al. Comparison of citalopram, perphenazine, and placebo for the acute treatment of psychosis and behavioral disturbances in hospitalized, demented patients. Am J Psychiatry 2002;159:460-5. (Pubitemid 34184743)
7. Seitz DP, Adunuri N, Gill SS, Gruneir A, Herrmann N, Rochon P. Antidepressants for agitation and psychosis in dementia. Cochrane Database Syst Rev 2011;2:CD008191.
8. Henry G, Williamson D, Tampi RR. Efficacy and tolerability of antidepressants in the treatment of behavioral and psychological symptoms of dementia, a literature review of evidence. Am J Alzheimers Dis Other Demen 2011;26:169-83.
9. Nelson JC, Devanand DP. A systematic review and meta-analysis of placebo-controlled antidepressant studies in people with depression and dementia. J Am Geriatr Soc 2011;59:577-85.
10. Bains J, Birks JS, Dening TR. The efficacy of antidepressants in the treatment of depression in dementia. Cochrane Database Syst Rev 2002;4:CD003944.
11. Banerjee S, Hellier J, Dewey M, Romeo R, Ballard C, Baldwin R, et al. Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomised, multicentre, double-blind, placebo-controlled trial. Lancet 2011;378:403-11.
12. Barca ML, Selbaek G, Laks J, Engedal K. Factors associated with depression in Norwegian nursing homes. Int J Geriatr Psychiatry 2009;24:417-25.
13. Coupland C, Dhiman P, Morriss R, Arthur A, Barton G, Hippisley-Cox J. Antidepressant use and risk of adverse outcomes in older people: population based cohort study. BMJ 2011;343:d4551.
14. Wetzels RB, Zuidema SU, de Jonghe JF, Verhey FR, Koopmans RT. Course of neuropsychiatric symptoms in residents with dementia in nursing homes over 2-year period. Am J Geriatr Psychiatry 2010;18:1054-65.
15. Alexopoulos GS, Abrams RC, Young RC, Shamoian CA. Cornell scale for depression in dementia. Biol Psychiatry 1988;23:271-84. (Pubitemid 18047596)
16. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994;44:2308-14. (Pubitemid 24382728)
17. Barca ML, Engedal K, Selbaek G. A reliability and validity study of the cornell scale among elderly inpatients, using various clinical criteria. Dement Geriatr Cogn Disord 2010;29:438-47.
18. Barca ML, Selbaek G, Laks J, Engedal K. The pattern of depressive symptoms and factor analysis of the Cornell Scale among patients in Norwegian nursing homes. Int J Geriatr Psychiatry 2008;23:1058-65.
19. Steinberg M, Tschanz JT, Corcoran C, Steffens DC, Norton MC, Lyketsos CG, et al. The persistence of neuropsychiatric symptoms in dementia: the Cache County Study. Int J Geriatr Psychiatry 2004;19:19-26. (Pubitemid 38180688)
20. Selbaek G, Engedal K. Stability of the factor structure of the Neuropsychiatric Inventory in a 31-month follow-up study of a large sample of nursing-home patients with dementia. Int Psychogeriatr 2012;24:62-73.
21. Berg L. Clinical dementia rating (CDR). Psychopharmacol Bull 1988;24:637-9. (Pubitemid 19054369)
22. Panisset M, Roudier M, Saxton J, Boller F. Severe impairment battery. A neuropsychological test for severely demented patients. Arch Neurol 1994;51:41-5. (Pubitemid 24020169)
23. Ballard C, McKeith I, Burn D, Harrison R, O'Brien J, Lowery K, et al. The UPDRS scale as a means of identifying extrapyramidal signs in patients suffering from dementia with Lewy bodies. Acta Neurol Scand 1997;96:366-71. (Pubitemid 28011093)
24. Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 1969;9:179-86.
25. Thorgrimsen L, Selwood A, Spector A, Royan L, de Madariaga LM, Woods RT, et al. Whose quality of life is it anyway? The validity and reliability of the Quality of Life-Alzheimer's Disease (QoL-AD) scale. Alzheimer Dis Assoc Disord 2003;17:201-8. (Pubitemid 37517787)
26. Bergh S, Engedal K. The withdrawal of antipsychotics and antidepressants from patients with dementia and BPSD living in nursing homes: an open pilot study. Int J Geriatr Psychiatry 2008;23:877-9.
27. Nyth AL, Gottfries CG. The clinical efficacy of citalopram in treatment of emotional disturbances in dementia disorders. A Nordic multicentre study. Br J Psychiatry 1990;157:894-901.
28. Siddique H, Hynan LS, Weiner MF. Effect of a serotonin reuptake inhibitor on irritability, apathy, and psychotic symptoms in patients with Alzheimer's disease. J Clin Psychiatry 2009;70:915-8.
29. Gaber S, Ronzoli S, Bruno A, Biagi A. Sertraline versus small doses of haloperidol in the treatment of agitated behavior in patients with dementia. Arch Gerontol Geriatr Suppl 2001;7:159-62. (Pubitemid 32727480)
30. Pollock BG, Mulsant BH, Rosen J, Mazumdar S, Blakesley RE, Houck PR, et al. A double-blind comparison of citalopram and risperidone for the treatment of behavioral and psychotic symptoms associated with dementia. Am J Geriatr Psychiatry 2007;15:942-52.
31. Lyketsos CG, DelCampo L, Steinberg M, Miles Q, Steele CD, Munro C, et al. Treating depression in Alzheimer disease: efficacy and safety of sertraline therapy, and the benefits of depression reduction: the DIADS. Arch Gen Psychiatry 2003;60:737-46. (Pubitemid 36818637)
32. Rosenberg PB, Drye LT, Martin BK, Frangakis C, Mintzer JE, Weintraub D, et al. Sertraline for the treatment of depression in Alzheimer disease. Am J Geriatr Psychiatry 2010;18:136-45.
33. Weintraub D, Rosenberg PB, Drye LT, Martin BK, Frangakis C, Mintzer JE, et al. Sertraline for the treatment of depression in Alzheimer disease: week-24 outcomes. Am J Geriatr Psychiatry 2010;18:332-40.